3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Enrolling by invitation
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Fasting
3
Prostatic Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Neoplasms
1
Lymphoma
1
Liposarcoma
1
Intermittent Fasting
1
Histiocytoma, Malignant Fibrous
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Childhood Cancer Survivors
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
61
Rituximab
50
fludarabine
34
Prednisone
33
Doxorubicin
28
Biopsy
26
Vincristine
25
Specimen Handling
22
Magnetic Resonance Spectroscopy
20
Bendamustine Hydrochloride
19
pembrolizumab
16
Lenalidomide
16
obinutuzumab
14
fludarabine phosphate
14
Etoposide
14
venetoclax
13
Tacrolimus
11
Mycophenolic Acid
10
Melphalan
10
Dexamethasone
10
zanubrutinib
9
ibrutinib
9
acalabrutinib
9
Radiotherapy
9
Gemcitabine
9
Cytarabine
9
Busulfan
9
Whole-Body Irradiation
8
Mesna
8
Filgrastim
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
Angptl4 protein, mouse
×
1 year
×
Clear all
NCT06645093
2026-03-10
FasteStudien
University of Oslo
Phase NA
Enrolling by invitation
40 enrolled